• Investing over $4 billion in Indiana fab and first ‘Made in USA’ next-generation HBM mass production in U.S. to begin in H2 2029
• Help stabilize the U.S. semiconductor supply chain and contribute to strengthening U.S. national security and economy
• Establishing a semiconductor ecosystem with more than 100 partners and creating 7,000 direct/indirect local jobs
• MOU with Purdue University for R&D collaboration on next-generation advanced packaging technology
• Recruitment of USFK (US Forces Korea) veterans, contributing to a stronger US-Korea alliance
• CEO Kwak Noh-Jung “We will become the most trusted partner in the U.S., where top-tier customers, R&D capabilities, and partners align”

SEOUL, South Korea, Aug. 28, 2026 /PRNewswire/ — SK hynix Inc. (or “the company”, www.skhynix.com) is opening a new future for AI cooperation between the United States and South Korea by establishing a first next-generation High Bandwidth Memory (HBM) production hub in the US.

SK hynix announced today that it held a groundbreaking ceremony for an advanced packaging^[1] production facility for AI memory on the 27^th (local time) at the Holloway Gymnasium, Purdue University, located in West Lafayette, Indiana.

The groundbreaking ceremony was attended by prominent US government and political figures, including Indiana Governor Mike Braun, US Senator Todd Young, Purdue University President Mitch Daniels, and Chairman of the Korea-US Alliance Foundation Robert Abrams. Kang Kyung-wha, Ambassador of South Korea to the United States, was also present at the event. From the SK Group, Vice Chairman Yu Jeong-Joon, Vice Chairman Lee Hyung-hee, CEO of SK hynix Kwak Noh-Jung attended.

Investment of Over $4 Billion for First US HBM Production Base Creating Synergy with Korea

The Indiana fab, with a total expected investment of over $4 billion, is scheduled to open its cleanroom by October 2028 and initiate mass production of next-generation HBM in the second half of 2029. It is projected to grow into a key HBM production hub in the US led by a workforce of approximately 1,000 personnel during anticipated commercial operations.

Notably, the Indiana fab marks SK hynix’s first HBM production base established in the United States, featuring an operation framework closely integrated with production in South Korea. Cutting edge wafers produced by SK hynix in Korea will be delivered to Indiana, where they will undergo advanced packaging and testing before Made in USA products are supplied to US customers.

Furthermore, an “Advanced Packaging R&D Testbed” will be built alongside the production lines, enabling customers, universities, and business partners to collaboratively develop next-generation packaging technologies and rapidly execute prototype fabrication and performance validation.

As competition to expand AI infrastructure intensifies, the Indiana fab, which connects SK hynix’s Korea-US HBM production, is expected not only to help stabilize the U.S. semiconductor supply chain but also to contribute to strengthening the national economy and security in the AI era.

“SK hynix’s historic investment in West Lafayette is further proof that Indiana is leading the way in rebuilding America’s semiconductor industry,” said Senator Young. “This project will create good-paying jobs, strengthen our national and economic security, and ensure the technologies of the future are developed and manufactured here in the United States. I was proud to help make this investment possible through the CHIPS and Science Act, and I look forward to seeing the impact it will have on Hoosiers and our country for decades to come.”

Indiana Governor Mike Braun remarked, “This project will usher in the next generation of American innovation, bring thousands of good-paying jobs to Indiana and supercharge regional economic development. It’s a win for Hoosiers, a win for our economy and a great leap forward for Indiana in the race to be the best in the industries of the future.”

Strengthening the Local Ecosystem and Bilateral Economic Cooperation with Local and National Companies

SK hynix’s investment in Indiana is expected to foster a virtuous cycle of strengthening the US semiconductor ecosystem and enhancing economic cooperation between South Korea and the United States.

Currently, more than 100 companies are being considered as suppliers for materials, components, and equipment for the West Lafayette facility, which will support the stable operation of the Indiana fab and further solidify the US AI ecosystem. SK hynix also plans to create approximately 7,000 direct and indirect jobs with local and national companies during construction of the advanced packaging facility and subsequent commercial operations.

Kang Kyung-wha, South Korean Ambassador to the US, stated, “SK hynix’s investment in Indiana is not merely an investment in semiconductor manufacturing facilities, but the establishment of the first AI memory production facility and R&D center in the United States, creating a unique model for nurturing semiconductor talent and strengthening collaboration with the government and external organizations.”

MOU for R&D Collaboration with Purdue University and Veteran Recruitment Program

At the groundbreaking ceremony, SK hynix also signed a Memorandum of Understanding (MOU) with Purdue University for research and development collaboration in the field of advanced packaging.

Through the MOU, both parties will strengthen R&D cooperation and will jointly research system integration and advanced packaging technologies, including HBM. In addition, SK hynix plans to expand efforts on cultivating and recruiting world-class talent from across the Midwest.

During the event, a recruitment partnership was also established to honor the special historical connection with Indiana, which deployed approximately 140,000 troops during the Korean War. SK Group agreed to provide new employment and career opportunities for discharged USFK service members. To this end, SK Group will participate as a hiring corporation in the ‘USFK Veterans Job Platform’ operated by the Korea Chamber of Commerce and Industry (KCCI) and the Korea-US Alliance Foundation, thereby contributing to the robust partnership between the two nations.

Kwak Noh-Jung, CEO of SK hynix, declared, “Today marks the day when the United States and SK hynix embark on a new future of AI together.” He added, “The United States is the epicenter of AI innovation, bringing together premier customers, top-tier R&D capabilities, and partners and Indiana fab will become a gateway to deliver first Made in USA HBM products.” He emphasized, “We will expand our investments and collaboration in the US, grow together, and become the most trusted partner in shaping the future of AI in America.”

Disclaimer

This material has been prepared by SK hynix for information purposes only, and the information contained herein has not undergone any separate, independent verification process. No representations or warranties are made regarding the fairness, accuracy, or completeness of the information contained in this material, and such information should not be relied upon. Neither SK hynix nor its employees bear any civil, criminal, or administrative liability for any damages arising from this material or from its use.

This material contains forward-looking statements, which involve risks and uncertainties. These statements are generally identified words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” and similar expressions, or the negative of such expressions. Forward-looking statements are not guarantees of future performance and are subject to inherent risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. SK hynix undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

This material does not constitute a solicitation for the acquisition or purchase of securities and no part of this material should serve as the basis for any contract, agreement, or investment decision, nor should it be relied upon in connection therewith.

About SK hynix Inc.

SK hynix Inc., headquartered in Korea, is the world’s top-tier semiconductor supplier offering Dynamic Random Access Memory chips (“DRAM”) and flash memory chips (“NAND flash”) for a wide range of distinguished customers globally. The Company’s common shares are traded on the Korea Exchange, its American Depositary Shares are traded on NASDAQ, and its Global Depository Shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.

GUANGZHOU, China, Aug. 27, 2026 /PRNewswire/ — Youxin Technology Ltd (Nasdaq: YAAS) (“Youxin Technology” or the “Company”), a software as a service (“SaaS”) and platform as a service (“PaaS”) provider, today announced its unaudited financial results for the first half of fiscal year 2026 ended March 31, 2026.

Mr. Shaozhang Lin, Chief Executive Officer of Youxin Technology Ltd, commented, “We delivered strong revenue growth for the first half of fiscal year 2026, with revenue increasing 444% and gross profit increasing 496%. Gross margin increased to 41% from 37% in the prior-year period. The increase in revenue was primarily attributable to the consolidation of Celnet Technology Co., Ltd. (“Celnet”), with the acquisition completed on October 29, 2025 (the “Acquisition”), together with the gradual growth from our customized CRM system development services.

“We are encouraged by the growing recognition of our third-generation PaaS platform as we expand partnerships with distributors, leading more customers to adopt and pay for our services. As we expand our distributor network and customer base, we anticipate additional opportunities to generate revenue from platform licenses and professional services. At the same time, as of March 31, 2026, we had continued advancing our PaaS platform from the third to fifth generation, incorporating an AI-powered digital enablement solution (“AI + PaaS”) while enhancing its functionality and performance in response to customer feedback and evolving market demand.

“Looking ahead, we will continue to strengthen relationships with distributors, prospective customers, government agencies, and industry partners to support the adoption of our platform. We also plan to continue investing in research and development to advance our AI-enabled digital solutions and support the commercialization and market development of our fifth-generation AI-powered PaaS platform. We believe these efforts will further strengthen our platform capabilities, broaden our customer and distribution network, and position us for long-term business growth.”

First Half of Fiscal Year 2026 Financial Overview

• Revenue was $1.88 million for the six months ended March 31, 2026, an increase of 444% from $0.35 million for the same period of last year.
• Gross profit was $0.77 million for the six months ended March 31, 2026, an increase of 496% from $0.13 million for the same period of last year.
• Gross margin was 41% for the six months ended March 31, 2026, an increase from 37% for the same period of last year.

First Half of Fiscal Year 2026 Financial Results

Revenues

Total revenues were $1.88 million for the six months ended March 31, 2026, an increase of 444% from $0.35 million for the same period of last year. The increase was mainly because the Company completed the acquisition of Celnet’s results of operations following the Acquisition on October 29, 2025, together with the gradual growth from its customized CRM system development services.

Revenue from professional services was $1.75 million for the six months ended March 31, 2026, or an increase of 662% from $0.23 million for the same period of last year.

• Revenue from customized CRM system development services was $0.83 million for the six months ended March 31, 2026, an increase of 274% from $0.22 million for the same period of last year. The increase was mainly due to the Company’s consolidation of Celnet and continue progressing the customized CRM system development service.
• Revenue from the data and workflow migration service, staff outsourcing service and operations and maintenance service was $0.36 million, $0.49 million, and $0.06 million for the six months ended March 31, 2026. The Company didn’t generate revenue from the data and workflow migration service, staff outsourcing service, or operations and maintenance service for the same period of last year. Revenue from the additional function development services was $21,935 for the six months ended March 31, 2026, an increase of 138% from $9,211 for the same period of last year. The increase was mainly primarily driven by growing demand for the function development from existing clients for the six months ended March 31, 2026.

Revenue from subscription service was $0.09 million for the six months ended March 31, 2026, or a decrease of 8% from $0.10 million for the same period of last year.

Revenue from payment channel services and others was $0.04 million for the six months ended March 31, 2026, or an increase of 125% from $0.02 million for the same period of last year.

Cost of Revenues

Cost of revenues was $1.11 million for the six months ended March 31, 2026, an increase of 413% from $0.22 million for the same period of last year.

Gross Profit

Gross profit was $0.77 million for the six months ended March 31, 2026, compared to $0.13 million for the same period of last year.

Gross margin was 41% for the six months ended March 31, 2026, an increase from 37% for the same period of last year.

Operating Expenses

Operating expenses were $2.65 million for the six months ended March 31, 2026, compared to $1.40 million for the same period of last year.

• Selling expenses were $0.26 million for the six months ended March 31, 2026, an increase of 156% from $0.10 million for the same period of last year. The increase was mainly due to the selling expenses incurred in Celnet of $0.21 million and the amortization of customer relationship of $0.04 million, which was due to the Acquisition.
• General and administrative expenses were $2.05 million for the six months ended March 31, 2026, an increase of 76% from $1.16 million for the same period of last year. The increase was primarily due to the general and administrative expenses incurred in Celnet of $0.25 million and the share-based compensation related to the shares issued to external consultants in exchange for professional services provided in the past of $0.64 million.
• Research and development expenses were $0.34 million for the six months ended March 31, 2026, an increase of 143% from $0.14 million for the same period of last year. The increase was primarily attributed to increased investment in AI-related development and higher salaries for research and development personnel for the six months ended March 31, 2026 compared to the six months ended March 31, 2025.

Other Income (Expense), Net

Total net other income was $0.03 million for the six months ended March 31, 2026, compared to a net other expense of $0.46 million for the same period of last year.

Net Loss

Net loss was $1.87 million for the six months ended March 31, 2026, compared to $1.74 million for the same period of last year.

Net Loss Attributable to Ordinary Shareholders

Net loss attributable to ordinary shareholders was $1.93 million for the six months ended March 31, 2026, compared to $1.74 million for the same period of last year.

Basic and Diluted Loss per Share

Basic and diluted loss per share was $0.20 for the six months ended March 31, 2026, compared to $0.19 for the same period of last year.

Financial Condition

As of March 31, 2026, the Company had cash of $4.55 million, compared to $9.91 million as of September 30, 2025.

Net cash used in operating activities was $1.21 million for the six months ended March 31, 2026, compared to $2.26 million for the same period of last year.

Net cash used in investing activities was $4.18 million for the six months ended March 31, 2026, compared to $3.44 million for the same period of last year.

Net cash provided by financing activities was $0.09 million for the six months ended March 31, 2026, compared to $7.24 million for the same period of last year.

About Youxin Technology Ltd

Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses through its cloud-based SaaS product and PaaS platform. The Company provides customized, comprehensive and fast-deployment omnichannel digital solutions to its customers. For more information, please visit the Company’s website: https://ir.youxin.cloud.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC. References and links (including QR codes) to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

For investor and media inquiries, please contact:

Youxin Technology Ltd
Investor Relations Department
Email: ir@youxin.cloud

Ascent Investor Relations LLC

Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

New service helps companies assess and strengthen their brand presence across AI assistants and search platforms

LONDON, Aug. 27, 2026 /PRNewswire/ — Frost & Sullivan today announced the launch of its AI Brand Equity and Market Presence service, powered by Optivara. This service enables companies to understand how they appear across AI answer engines, how they compare to competitors, their competitive placement by funnel stage, and whether AI-generated market narratives reflect the position they have worked to build.

Designed for marketing, brand, communications and strategy leaders seeking to understand how AI systems represent their organisations throughout the buyer journey, the service identifies visibility gaps, competitive advantages, narrative inconsistencies and the external sources influencing AI-generated answers. These findings are translated into prioritised actions spanning content, messaging, digital authority, third-party validation and market positioning.

For two decades, digital discovery was shaped largely by search engines. Today, buyers are increasingly asking AI systems which suppliers to consider, how companies compare, what risks to evaluate, and which providers are best positioned for their needs. These AI systems are effectively becoming top-of-funnel sales reps.

The service combines Optivara’s AI industry-tuned market presence platform with Frost & Sullivan’s industry expertise, analyst insights, and subject-matter expert validation. Clients receive a market presence benchmark, a competitive peer map, an AI-answer narrative review, a source diagnosis, and a detailed SWOT analysis. From that, an actionable roadmap to better control AI brand dynamics and drive demand is developed and implemented.

“AI is quickly becoming part of how buyers form a first impression of a market, a category, and a supplier,” said Brian Cotton, Senior Vice President of Growth Advisory at Frost & Sullivan. “What makes this service so valuable is not just the technology. It is Frost & Sullivan’s ability to help tune the Optivara platform and interpret the findings through an industry lens. Our analysts and subject matter experts understand the market context, the competitors, the buying criteria, and the strategic shifts our clients are trying to make. That is the difference between getting data and getting results.”

“Optivara was built to reverse-engineer how AI thinks about companies, why they are being represented that way, and what can be done to improve it,” said George Schoenstein, Co-Founder at Optivara. “Partnering with Frost & Sullivan brings an important layer of market expertise and industry-tuning to the process. Together, we can help leadership teams understand whether AI is reinforcing their strategy, missing their story, or allowing competitors and third-party sources to define the narrative. Together, this enables companies to optimise the impact of their marketing dollars.”

To learn more about Frost & Sullivan’s AI Brand Equity and Market Presence advisory services, or request an introductory consultation and demonstration, contact Brian Cotton at brian.cotton@frost.com.

About Frost & Sullivan
Frost & Sullivan, the Growth Pipeline Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth opportunities. For over 60 years, Frost & Sullivan has partnered with investors, corporate leaders, and governments to identify, prioritise, and execute transformational growth strategies.

Your Transformational Growth Journey Starts Here: Schedule Your Growth Pipeline Dialog™ with the Frost & Sullivan team.

Contact:
Kristina Menzefricke
Marketing & Communications
Global Customer Experience, Frost & Sullivan
kristina.menzefricke@frost.com

About Optivara
Optivara is the industry-tuned Generative Engine Optimization (GEO) platform built for agencies. We help agency teams measure and improve client AI answer engine performance by reverse-engineering competitors and top performers in a segment and translating those insights into a roadmap and SWOT analysis to win across the entire customer journey. Our human-in-the-loop, industry-tuned expert models show exactly what to do to improve visibility, reputation, and geographic answer engine performance, while our Generative Positioning Score™ (GPS) provides a consistent way to measure progress over time. To learn more, visit www.optivara.ai or contact pr@optivara.ai

Highlights:

• Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
• Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
• Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group’s total revenue;
• Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7 innovative drugs approved for launch both domestically and overseas;
• Adhering to proactive and prudent liquidity and debt management, Fosun generated proceeds equivalent to more than RMB12.0 billion from the divestment of non-strategic and non-core assets in the first half of the year, bringing the total debt to total capital ratio down to 55.7%;
• MSCI ESG rating was upgraded to the highest rating of AAA, reflecting continued recognition from international authoritative institutions.

HONG KONG, Aug. 27, 2026 /PRNewswire/ — Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its interim results for the six months ended 30 June 2026 (the “Reporting Period”).

In the first half of 2026, Fosun continued to advance its business streamlining and core business-focused strategy. Powered by the twin engines of innovation and globalization, the operational quality of its core industries, including pharmaceuticals and healthcare, insurance and finance, and cultural tourism and consumer businesses, steadily improved and gained collective momentum, driving a notable increase in profitability. During the Reporting Period, the Group’s total revenue reached RMB86.96 billion, remaining broadly stable despite the continued divestment of non-strategic and non-core assets; industrial operation profit reached RMB3.69 billion, representing a year-on-year increase of 17%; and profit attributable to owners of the parent reached RMB1.72 billion, representing a significant year-on-year increase of 160.3%.

During the Reporting Period, Fosun’s asset base remained solid, with its subsidiaries Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and Fosun’s Tourism segment generating a total revenue of RMB63.88 billion, accounting for 73.5% of the Group’s total revenue. Overseas revenue reached RMB49.16 billion, representing a year-on-year increase of 5.3%. Its share of total revenue rose by 3 percentage points to 56.5%, underscoring the success of its globalization strategy.

Meanwhile, Fosun adhered to proactive and prudent liquidity and debt management, maintaining sufficient liquidity buffer. During the Reporting Period, the Group generated proceeds equivalent to more than RMB12.0 billion from the divestment of non-strategic and non-core assets. As at 30 June 2026, cash, bank balances and term deposits amounted to RMB61.214 billion, an increase compared to the end of 2025; the total debt to total capital ratio was 55.7%, a further decrease compared to the end of 2025. A healthy debt ratio and ample cash reserves strengthen the Group’s risk resilience while also enhancing its capacity to seize investment opportunities.

Guo Guangchang, Chairman of Fosun International, said: “Over the past few years, Fosun has steadfastly advanced its business streamlining and core business-focused strategy, and completed a systematic realignment of ‘repairing the roof on a sunny day’. The strong earnings recovery we delivered in the first half of this year validates our strategic direction and sustained focus. Fosun has now returned to a growth trajectory and is well-positioned to accelerate its growth going forward.”

Adhering to Innovation-Driven Development, Innovative Drugs Enter a Period of Intensive Approvals and Value Realization

In the first half of 2026, Fosun remained committed to innovation-driven development, fully embraced AI applications, accelerated the conversion of its technology innovations into tangible value, and continued to enhance operational efficiency. During the Reporting Period, Fosun’s investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Its global innovation system integrating “independent R&D + investment incubation + ecosystem collaboration” continued to gain momentum, fostering a series of globally competitive innovations.

With a focus on addressing unmet clinical needs, Fosun’s Health segment delivered notable technology innovation achievements. During the Reporting Period, innovative drugs entered a period of intensive approvals and value realization. Fosun Pharma had a total of 20 indications of 7 innovative drugs approved for launch both domestically and overseas. Among them, FUMAINING (luvoxmetinib tablets) was approved for the treatment of paediatric and adolescent patients with relapsed or refractory Langerhans cell histiocytosis (LCH), continuing to fill the gap in the treatment of rare diseases. In terms of neurodegenerative diseases, Fosun Pharma continued to advance its innovation pipeline. Building upon the rights obtained to develop, register, manufacture and exclusively commercialize AR1001 in Chinese mainland, Hong Kong SAR, Macau SAR, and 10 agreed Southeast Asian countries, Fosun Pharma further secured a global exclusive option for AR1001, with the right to exercise the option, thereby expanding the licensed territory to key global markets including the U.S., Europe and Japan, where it would act as the marketing authorization holder in such regions. Meanwhile, post-marketing confirmatory clinical trials for sodium oligomannate capsules in Chinese mainland have progressed steadily, with more than 1,000 patients enrolled as of 31 July 2026. In addition, HT001, an oral brain-penetrant NLRP3 inhibitor for the treatment of Parkinson’s disease in-licensed by Hengtai Bio, an investee and incubated company of Fosun Pharma, commenced its Phase I clinical trial in Australia.

As a core subsidiary in the Health segment, Fosun Pharma achieved operating revenue of RMB20.377 billion. Revenue from innovative drugs recorded a year-on-year increase of 13.84%, with their contribution to pharmaceutical business revenue rising to 33.35%, establishing innovative drugs as a key growth driver.

In terms of biologic innovative drugs, Fosun continued to deliver breakthroughs in the first half of the year. HANSIZHUANG, independently developed by Henlius, received approval from the National Medical Products Administration (NMPA) for its perioperative indication in gastric cancer, making it the world’s first and only anti-PD-1 monoclonal antibody approved for this indication and pioneering a postoperative “chemo-sparing” regimen. HLX43, a core asset in the innovative pipeline, is a potential best-in-class (BIC) broad-spectrum anti-tumor PD-L1 ADC. It has demonstrated preliminary clinical efficacy characterized by high efficacy and low toxicity across multiple solid tumors, including non-small cell lung cancer (NSCLC). To date, more than ten clinical studies of HLX43 as monotherapy or in combination regimens have been initiated, with over 1,500 patients enrolled globally, continuing to evaluate its broad therapeutic potential across multiple solid tumors.

During the Reporting Period, Henlius showcased strong organic growth momentum and sustainable earnings generation, with revenue reaching RMB3.5882 billion, representing a year-on-year increase of 27.3%, and net profit amounting to RMB430.4 million, up 10.3% year-on-year.

Amid the AI wave, Fosun deepened the application of AI across its core businesses and global industrial ecosystem, with a focus on harnessing AI to deliver “practical productivity” and creating tangible industry value.

Fosun Pharma completed the upgrade of its “PharmAID® Pharmaceutical Intelligence Platform V2.0”, establishing four key components to support AI-powered product development across the full lifecycle, from early-stage R&D and clinical validation to post-launch commercialization. As of the end of the Reporting Period, Fosun Pharma had rolled out more than 25 high-value AI projects, with more than 50 use cases simultaneously underway. These initiatives span multiple business functions, including pharmaceutical project evaluation, target prediction and molecule optimization. Two AI‑assisted and structurally generated new molecules have entered the preclinical candidate (PCC) stage. In March 2026, the next-generation recombinant human hyaluronidase (rHuPH20) injection, independently developed by Henlius, was approved to begin clinical trials in China. Leveraging its “AI for Science” platform, Henlius significantly shortened the enzyme-molecule design cycle from 18 months to 5 months.

Beyond pharmaceuticals, Fosun deeply integrated AI into its cultural tourism, insurance, and intelligent manufacturing businesses. Fosun’s Tourism segment accelerated the implementation of “AI G.O” and partnered with a leading technology company to engage in deep collaboration across three key areas: using AI to enhance guest experience, advancing its transition to cloud- and AI-native platforms, and supporting global growth. Leveraging the resource demand brought about by AI technologies, Hainan Mining swiftly expanded its presence in core upstream resources such as fluorite.

Deepening Global Operations to Enhance Quality and Efficiency, Domestic and Overseas Insurance Companies Deliver Broad-Based Improvements

Supported by its business presence and profound operations in more than 40 countries and regions worldwide, Fosun comprehensively advanced its strategy of “Combining Global Resources with China’s Capabilities”, deeply integrating China’s manufacturing capabilities, service capabilities, and innovation dividends with the global market. During the Reporting Period, the Group’s overseas revenue reached RMB49.16 billion, accounting for 56.5% of total revenue.

In the first half of 2026, Fosun’s subsidiaries continued to build on their globalization capabilities, achieving a series of major breakthroughs in international expansion.

In the field of healthcare, Fosun Pharma’s overseas business revenue grew 16.45% year-on-year, accounting for 31.30% of total revenue.This represents an uplift of 3.11 percentage points, and the revenue mix continues to improve. Henlius’ HANSIZHUANG was approved for three new indications in the European Union (EU), while HLX11 (pertuzumab injection) was approved in the EU and two HLX14 (denosumab injection) products were approved and commercially launched in Canada. To date, Henlius has 10 products approved in over 60 countries and regions across Asia, Europe, Latin America, North America, and Oceania, and has benefited over 1.1 million patients worldwide. Fosun Health continued to advance its internationalization strategy, actively expanding into markets such as Indonesia, Bangladesh, Mongolia, Hong Kong SAR, and Macau SAR, while building an open, stable, and professional international medical collaboration network. In addition, the International Medical Center of Foshan Fosun Chancheng Hospital was officially inaugurated, forming a full-process, closed-loop international medical service system.

In terms of the consumer and cultural tourism businesses, Yuyuan generated revenue of RMB532 million in Hong Kong SAR and Macau SAR in the first half of 2026, representing a year-on-year increase of 285.83%, while revenue from the Japanese market reached RMB306 million, representing a year-on-year increase of 6.09%. The jewelry business also made notable progress in overseas expansion. Laomiao opened 5 new stores in Hong Kong SAR, Macau SAR, overseas markets and duty-free channels, bringing the total number of stores across these channels to 15. Club Med continued to expand its global destination network. Club Med Urban Oasis Hangzhou Longwu officially opened in April 2026, while Club Med South Africa Beach & Safari had its soft opening in July 2026.

In the intelligent manufacturing segment, Hainan Mining’s integrated value chain of “Bougouni Lithium Mine in Mali + Hainan Xingzhihai Lithium Salt Processing” operated steadily, serving as a key driver of the company’s earnings growth. It completed the delivery of three shipments totaling 70,000 tons of lithium concentrate from Mali, Africa, to Yangpu Port in Hainan, China in the first half of the year. Wansheng’s phosphate ester flame retardant project at its Thailand facility successfully commenced operations, filling the gap in Wansheng’s overseas manufacturing footprint in this area and further strengthening the resilience of its global supply chain.

With the ongoing advancement of its globalization strategy, Fosun’s domestic and overseas insurance companies delivered broad-based improvements in the first half of 2026. As of the end of the Reporting Period, Fidelidade held a 30.1% overall market share in Portugal, its international business accounted for 26.7% of its consolidated total business, while gross written premiums from overseas markets reached EUR1.035 billion. Despite losses from multiple storms in Portugal during the Reporting Period, Fidelidade recorded net profit attributable to owners of the parent of EUR165 million, up 23.8% year-on-year.

Benefiting from its high-quality client base, disciplined underwriting and global business footprint, Peak Reinsurance maintained solid performance. During the Reporting Period, reinsurance revenue and gross written premiums increased by 25.0% and 11.8% year-on- year, respectively, while net profit after tax reached USD89.70 million. Building on its sound financial strength and growing market position, Moody’s upgraded Peak Re’s rating from Baa1 to A3 in April 2026, with a “stable” outlook.

In Chinese mainland, Pramerica Fosun Life Insurance recorded gross written premiums of RMB8.38 billion in the first half of 2026, up 52.2% year-on-year. Net profit reached RMB780 million, representing a year-on-year increase of 270% and exceeding its net profit for the full year of 2025. Fosun United Health Insurance reported a 36.2% year-on-year increase in revenue and net profit of RMB572 million.

Committed to Business for Good, MSCI ESG Rating Upgraded to AAA

During the Reporting Period, Fosun continued to gain international recognition for its environmental, social and governance (ESG) performance. Its MSCI ESG rating was upgraded to the highest rating of AAA. It was once again included in S&P Global’s Sustainability Yearbook 2026 and ranked among the top 1% in the Sustainability Yearbook (China Edition) 2026. In addition, its FTSE Russell ESG score remained above the global industry and Chinese corporate averages. It was selected as a constituent of the FTSE4Good Index Series for the fifth consecutive year.

Fosun consistently contributed the “China Solution” to malaria control efforts in Africa. As of the end of the Reporting Period, Fosun Pharma had cumulatively supplied more than 460 million vials of its independently developed artesunate for injection worldwide, saving more than 92 million patients with severe malaria. The “Seasonal Malaria Chemoprevention Program”, centered on the SPAQ-CO® series of products, has benefited more than 330 million children in Africa.

The “Rural Doctors Program”, initiated by Fosun Foundation, continued to cover 78 project counties in 16 provinces, cities and autonomous regions, supporting 25,000 rural doctors and benefiting 3 million rural families and 16.34 million rural residents. In the first half of 2026, the program provided a total of more than 12,590 group accidental and critical illness insurance policies for rural doctors in project counties, carried out intelligent upgrading for 59 clinics or hospitals, and supported 263 rural doctors in obtaining the qualification of Assistant General Practitioner. Launched in May, the “AI Rural Doctor Assistant 2.0” achieved a 100% service-success rate and a 92% user-satisfaction rate among rural doctors.

Looking ahead, Guo Guangchang said: “The earnings recovery we delivered in the first half of the year was no coincidence. It was the result of Fosun’s long-term commitment and sustained focus on its core businesses. Going forward, we will continue to advance innovation-driven and global development in industries where we have established competitive advantages. With a clear path ahead, we are confident that we can steadily restore annual profit to the RMB10 billion level.”